title: [Interferon alfa-2b treatment in selected cases of recurrent conjunctival intraepithelial neoplasia].
abstract: OBJECTIVE
  To study the efficacy of topical and combined topical and subconjunctival interferon alfa 2b (IFN alfa 2b) in the treatment of recurrent conjunctival intraepithelial neoplasia (CIN) in those patients who present resistance or intolerance to topical mitomycin C (MMC) treatment or when it is not indicated.
  
  
  METHODS
  Four patients (age range from 52 to 70) with histological confirmation of recurrent CIN were studied prospectively. Two patients were resistant to topical MMC, another one did not tolerate it, and in the last case, this treatment was not indicated due to a stem cell insufficiency associated to a trophic corneal ulcer. Three patients were given just topical interferon (1 million IU/ ml four times a day for three months), while the last one received topical therapy and subconjunctival IFN alfa 2b injections (3 millions IU/ 0.5 ml).
  
  
  RESULTS
  Complete regression of the tumour was evident in all cases. sixteen to 24 months after treatment no patient had clinical evidence of recurrence. No side effects were observed in any patient, not even with subconjunctival administration.
  
  
  CONCLUSIONS
  IFN alfa 2b is effective as an alternative treatment to topical MMC in selected cases of recurrent CIN.
authors.affiliation: Hospital General de Móstoles, Madrid, España.
authors.forename: N
authors.initials: N
authors.lastname: Toledano Fernández
authors.forename: S
authors.initials: S
authors.lastname: García Sáenz
authors.forename: D
authors.initials: D
authors.lastname: Díaz Valle
authors.forename: A
authors.initials: A
authors.lastname: Arteaga Sánchez
authors.forename: M
authors.initials: M
authors.lastname: Segura Bedmar
authors.forename: S
authors.initials: S
authors.lastname: Lorenzo Giménez
authors.forename: L
authors.initials: L
authors.lastname: Cortés Lambea
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D011446:Prospective Studies; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins